MedTrace Logo

Efficacy and Safety of LX9211 in Participants With Postherpetic Neuralgia

NCT04662281 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 79

Last updated 2026-02-13

Study results available
· View outcomes & findings →

Summary

Evaluation of the efficacy of LX9211 compared to placebo in reducing pain related to postherpetic neuralgia over an 11 week assessment period.

Conditions

  • Postherpetic Neuralgia

Interventions

DRUG

Placebo

LX9211 matching-placebo, tablets will be administered orally.

DRUG

LX9211

LX9211 tablets will be administered orally.

Sponsors & Collaborators

  • Lexicon Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Suma Gopinathan, PhD · Lexicon Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-12-10
Primary Completion
2022-11-18
Completion
2022-12-28
FDA Drug
Yes

Countries

  • United States
  • Czechia
  • Poland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04662281 on ClinicalTrials.gov